Tracking Real-Life results of new cancer immunotherapy
NCT ID NCT07173244
Summary
This study aims to learn about the real-world safety and effectiveness of the immunotherapy drug adebrelimab in people with advanced solid tumors, primarily lung and gastrointestinal cancers. It will observe 300 patients who have already decided with their doctor to receive this treatment as part of their standard care. Researchers will collect information on side effects, treatment details, and how patients fare over time to better understand how the drug performs outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.